Propionyl L-carnitine and Physical Training for Intermittent Claudication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for intermittent claudication due to peripheral arterial disease primarily focus on pharmacological interventions, which may have limitations in improving both objective symptomatic and subjective quality of life, and do not adequately address the need for long-term patient compliance and safety, especially when combined with physical exercise recommendations that are not systematically integrated into the treatment protocol.
Innovation Solution
Administering an effective dose of propionyl L-carnitine concurrently with a prescribed physical training program, tailored to the patient's severity and condition, to enhance exercise tolerance and quality of life in patients with intermittent claudication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacological interventions are used to treat intermittent claudication, then symptomatic improvement is achieved, but patient compliance and long-term safety are compromised
Solution Approach 1:
The patent combines propionyl L-carnitine administration with a structured physical training program into a single integrated treatment protocol. This merging of pharmacological and physical therapy approaches creates a comprehensive treatment that addresses both metabolic dysfunction and exercise capacity, improving overall compliance while maintaining symptomatic relief.
Solution Approach 2:
The patent introduces specific dosage parameters for propionyl L-carnitine (2-4 grams daily) and structured exercise parameters (frequency, intensity, duration, type) to optimize treatment effectiveness. These parameter changes transform the treatment from a purely pharmacological approach to a standardized protocol that improves compliance through clear, measurable guidelines.
2Duration of action of moving object
If pharmacological treatments are administered alone, then short-term symptomatic relief is achieved, but long-term quality of life improvement is limited
Solution Approach 1:
The patent employs propionyl L-carnitine as a preliminary metabolic intervention that prepares the muscle tissue for subsequent physical training. This preliminary action addresses the underlying metabolic dysfunction before the physical training component, creating optimal conditions for long-term adaptation and sustained quality of life improvement.
Solution Approach 2:
The patent establishes a continuous treatment protocol where propionyl L-carnitine administration and physical training occur concurrently over an extended period. This continuity ensures sustained metabolic support during exercise adaptation, transforming short-term symptomatic relief into long-term quality of life improvement through persistent therapeutic action.
3Ease of operation
If physical exercise is recommended separately from pharmacological treatment, then general health advice is provided, but integrated therapeutic benefit is not achieved
Solution Approach 1:
The patent merges propionyl L-carnitine administration with a structured physical training program into a single integrated treatment protocol. This merging of pharmacological and physical therapy approaches creates a comprehensive treatment that addresses both metabolic dysfunction and exercise capacity, improving overall compliance while maintaining symptomatic relief.
Data Source
AI summary
The present invention discloses a method for treating a subject suffering from intermittent claudication (IC) wherein said subject takes an effective dose of propionyl L-carnitine or a pharmaceutically acceptable salt thereof and also engaging in a concomitant physical training program. The method is particular effective for patients with intermittent claudication at class II of the Leriche-Fontaine's classification. The method provides a relief from peripheral arterial disease symptoms, as shown by claudication-limited exercise tolerance, while also improving quality of life.